Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.

AUPH

Aurinia Pharmaceuticals (AUPH)

Aurinia Pharmaceuticals Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:AUPH
DateTimeSourceHeadlineSymbolCompany
23/05/202406:16Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AUPHAurinia Pharmaceuticals Inc
23/05/202406:14Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AUPHAurinia Pharmaceuticals Inc
23/05/202406:11Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AUPHAurinia Pharmaceuticals Inc
23/05/202406:09Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AUPHAurinia Pharmaceuticals Inc
23/05/202406:07Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AUPHAurinia Pharmaceuticals Inc
14/05/202420:00Business WireAnalysis Showing LUPKYNIS® is a Cost-Effective Treatment for Lupus Nephritis Presented at National Kidney Foundation’s Spring Clinical Meeting 2024NASDAQ:AUPHAurinia Pharmaceuticals Inc
09/05/202420:00Business WireAurinia Presents Data Reinforcing LUPKYNIS® Safety and Efficacy for People with Lupus Nephritis at Congress of Clinical Rheumatology East 2024NASDAQ:AUPHAurinia Pharmaceuticals Inc
07/05/202420:00Business WireAurinia Will Attend 2024 RBC Capital Markets Global Healthcare ConferenceNASDAQ:AUPHAurinia Pharmaceuticals Inc
02/05/202420:00Business WireAurinia Pharmaceuticals Reports First Quarter 2024 Financial and Operational ResultsNASDAQ:AUPHAurinia Pharmaceuticals Inc
01/05/202420:00Business WireAurinia Underscores Enduring Commitment to People Living with Lupus Nephritis Through Innovative Advocacy and Education Initiatives for Lupus Awareness MonthNASDAQ:AUPHAurinia Pharmaceuticals Inc
30/04/202420:00Business WireThe U.S. Food & Drug Administration (FDA) Approves Updated LUPKYNIS® (voclosporin) Label to include Long-Term Data from the AURORA Clinical ProgramNASDAQ:AUPHAurinia Pharmaceuticals Inc
17/04/202400:48Business WireUPDATE: New Aurinia Presentation Details at the 2024 Bloom Burton & Co. Healthcare Investor ConferenceNASDAQ:AUPHAurinia Pharmaceuticals Inc
15/04/202420:00Business WireAurinia Pharmaceuticals to Release First Quarter Financial and Operational Results on May 2, 2024NASDAQ:AUPHAurinia Pharmaceuticals Inc
09/04/202420:00Business WireAurinia Will Attend 2024 Bloom Burton & Co. Healthcare Investor ConferenceNASDAQ:AUPHAurinia Pharmaceuticals Inc
08/03/202408:44Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AUPHAurinia Pharmaceuticals Inc
08/03/202408:43Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AUPHAurinia Pharmaceuticals Inc
08/03/202408:42Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AUPHAurinia Pharmaceuticals Inc
08/03/202408:41Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AUPHAurinia Pharmaceuticals Inc
01/03/202408:10Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:AUPHAurinia Pharmaceuticals Inc
01/03/202400:30Business WireAurinia Receives Exemptive Relief from Canadian Securities Regulators for Share Repurchase ProgramNASDAQ:AUPHAurinia Pharmaceuticals Inc
28/02/202400:30Business WireAurinia to Participate in Upcoming Investor Healthcare ConferencesNASDAQ:AUPHAurinia Pharmaceuticals Inc
23/02/202408:35Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AUPHAurinia Pharmaceuticals Inc
23/02/202408:33Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AUPHAurinia Pharmaceuticals Inc
23/02/202408:31Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AUPHAurinia Pharmaceuticals Inc
23/02/202408:29Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AUPHAurinia Pharmaceuticals Inc
23/02/202408:27Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AUPHAurinia Pharmaceuticals Inc
23/02/202408:19Edgar (US Regulatory)Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]NASDAQ:AUPHAurinia Pharmaceuticals Inc
23/02/202408:17Edgar (US Regulatory)Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]NASDAQ:AUPHAurinia Pharmaceuticals Inc
15/02/202422:16Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:AUPHAurinia Pharmaceuticals Inc
15/02/202422:06Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:AUPHAurinia Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:AUPH